Lab Anim Res.  2018 Jun;34(2):80-83. 10.5625/lar.2018.34.2.80.

Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in response to inflammatory stimulation in rats

• Kuribayashi T

• KMID: 2413847
• DOI: http://doi.org/10.5625/lar.2018.34.2.80

Abstract

The elimination half-lives of in Interleukin-6 (IL-6) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) in rats after inflammatory stimulation were investigated. Five male Sprague-Dawley rats were used (age, 9 weeks; body weight, 235-375 g). Turpentine oil was intramuscularly injected at a dose of 2 mL/kg body weight to induce acute inflammation. Blood was collected pre-injection and 6, 12, 24, 36, 48, 60, 72, 84, and 96 h after the turpentine oil injection. Serum concentrations of IL-6, CINC-1, and α₂-macroglobulin (α2M) were measured by enzyme-linked immunosorbent assay. Half-lives were calculated as 0.693/elimination rate constant. The serum concentration of α2M peaked at 48 h after turpentine oil injection. Serum concentrations of IL-6 and CINC-1 increased and peaked at 12 and 24 h, respectively. The terminal elimination half-lives of IL-6 and CINC-1 were 15.5 and 29.9 h, respectively. The half-life of CINC-1 was significantly longer than that of IL-6 (P=0.006). These results suggested that these cytokines synthesized in response to inflammatory stimulation were rapidly eliminated in rats. The serum concentrations of these cytokines should be measured at an early stage if these cytokines will be used as surrogate inflammatory markers instead of acute-phase proteins.

Keyword

Half-life; IL-6; CINC-1; rat; α2M

MeSH Terms

Acute-Phase Proteins
Animals
Body Weight
Cytokines
Enzyme-Linked Immunosorbent Assay
Half-Life
Humans
Inflammation
Interleukin-6*
Male
Neutrophils*
Rats*
Rats, Sprague-Dawley
Turpentine
Acute-Phase Proteins
Cytokines
Interleukin-6
Turpentine

Figure

• 

  Figure 1 Serum concentrations of α2-macroglobulin (α2M) in rats after injection of turpentine oil at dose of 2 mL/kg body weight. Each point represented as mean±standard deviation (n=5).

• 

  Figure 2 Serum concentrations of interleukin-6 (IL-6) in rats after injection of turpentine oil at dose of 2 mL/kg body weight (n=5). Each point represented as mean±standard deviation (n=5). IL-6 was not detected (ND) except for 1 rats at 72 hours after injection of turpentine oil and ND was calculated as zero. IL-6 was not detected at 84 and 96 hours after injection in all rats.

• 

  Figure 3 Serum concentrations of cytokine-induced neutrophil chemoattractant-1 (CINC-1) in rats after injection of turpentine oil at dose of 2 mL/kg body weight (n=5). Each point represented as mean±standard deviation (n=5).

Reference

1. Inoue S, Jinbo T, Shino M, Iguchi K, Nomura M, Kawato K, Yamamoto S. Determination of α₂-macroglobulin concentrations in healthy rats of various ages and rats inoculated with turpentine oil by an enzyme-linked immunosorbent assay. J Exp Anim Sci. 2001; 42(1):44–49.

2. Jinbo T, Motoki M, Yamamoto S. Variation of serum α₂-macroglobulin concentration in healthy rats and rats inoculated with Staphylococcus aureus or subjected to surgery. Comp Med. 2001; 51(4):332–335. PMID: 11924791.

3. Jinbo T, Sakamoto T, Yamamoto S. Serum α₂-macroglobulin and cytokine measurements in an acute inflammation model in rats. Lab Anim. 2002; 36(2):153–157. PMID: 11943079.

4. Honjo T, Kuribayashi T, Seita T, Mokonuma Y, Yamaga A, Yamazaki S, Yamamoto S. The effects of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 on α₂-macroglobulin production in rats. Exp Anim. 2010; 59(5):589–594. PMID: 21030786.

5. Kuribayashi T, Tomizawa M, Seita T, Tagata K, Yamamoto S. Relationship between production of acute-phase proteins and strength of inflammatory stimulation in rats. Lab Anim. 2011; 45(3):215–218. PMID: 21669904.

6. Kuribayashi T, Seita T, Kawato K, Yamazaki S, Yamamoto S. Comparison of α₂-macroglobulin synthesis by juvenile vs. mature rats after identical inflammatory stimulation. Inflammation. 2013; 36(6):1448–1452. PMID: 23856939.

7. Honjo T, Kuribayashi T, Matsumoto M, Yamazaki S, Yamamoto S. Kinetics of α₂-macroglobulin and α₁-acid glycoprotein in rats subjected to repeated acute inflammatory stimulation. Lab Anim. 2010; 44(2):150–154. PMID: 19858170.

8. Kuribayashi T, Seita T, Honjo T, Yamazaki S, Momotani E, Yamamoto S. Impairment of α₂-macroglobulin synthesis in experimental hepatopathic rats treated with turpentine oil. Exp Anim. 2012; 61(2):125–130. PMID: 22531727.

9. Todd I, Spickett G. Lecture notes Immunology. 6th ed. USA: Wiley-Blackwell;2011. p. 42–54.

10. Weber RL, Iacono VJ. The cytokines: a review of interleukins. Periodontal Clin Investig. 1997; 19(1):17–22.

11. Whiteside TL. Cytokine assays. Biotechniques. 2002; 33:S4–S15.

12. Prasad VG, Vivek Ch, Anand Kumar P, Ravi Kumar P, Rao GS. Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetion without altering its elimination process in rats. Eur J Drug Metab Pharmacokinet. 2015; 40(1):23–28. PMID: 24356809.

13. Veilleux-Lemieux D, Castel A, Carrier D, Beaudry F, Vachon P. Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. J Am Assoc Lab Anim Sci. 2013; 52(5):567–570. PMID: 24041212.

14. Rycroft D, Sosabowski J, Coulstock E, Davies M, Morrey J, Friel S, Kelly F, Hamatake R, Oveèka M, Prince R, Goodall L, Sepp A, Walker A. Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha. PLoS One. 2015; 10(2):e0117847. PMID: 25689509.

15. Kuribayashi T, Seita T, Momotani E, Yamazaki S, Hagimori K, Yamamoto S. Elimination half-lives of acute-phase proteins in rats and beagle dogs during acute inflammation. Inflammation. 2015; 38(4):1401–1405. PMID: 25633424.

16. Hu X, Shang S, Nestorov I, Hasan J, Seddighzadeh A, Dawson K, Sperling B, Werneburg B. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. Br J Clin Pharmacol. 2016; 82(2):380–388. PMID: 27060836.

17. Grace MJ, Cutler D. Pegylating IFNs at His-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother. 2004; 15(6):287–297. PMID: 15646642.

18. Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010; 70(2):147–165. PMID: 20108989.

19. White JT, Newsome SD, Kieseier BC, Bermel RA, Cui Y, Seddighzadeh A, Hung S, Crossman M, Subramanyam M. Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Ther Adv Neurol Disord. 2016; 9(4):239–249. PMID: 27366230.

20. Yamazaki N, Uhara H, Wada H, Matsuda K, Yamamoto K, Shimamoto T, Kiyohara Y. Phase I study of pegylated interferon-alpha-2a as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol. 2016; 43(10):1146–1153. PMID: 27087489.